Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
dTub
Скачать

TAGRISSO® (osimertinib): A Musician's Story

Автор: TAGRISSO® (osimertinib)

Загружено: 2025-01-15

Просмотров: 1281

Описание:

If you or someone you love has stage 4 EGFR+ NSCLC, TAGRISSO may be able to help. Talk to your doctor to see if TAGRISSO may be right for you. This is not an actual patient story.

Please see full Important Safety Information at    • Important Safety Information  

Please see complete Prescribing Information, including Patient Information for TAGRISSO available at https://www.azpicentral.com/pi.html?p...

SELECT SAFETY INFORMATION

TAGRISSO is an FDA-approved oral targeted therapy used as a first treatment for metastatic non-small cell lung cancer (NSCLC) with certain abnormal EGFR gene(s).

TAGRISSO may cause serious side effects, some may be severe. These could lead to death. Tell your healthcare provider right away if you have lung problems, such as trouble breathing, shortness of breath, cough, or fever; heart problems, such as pounding or racing, swelling of your ankles and feet, dizziness, feeling lightheaded, or feeling faint; eye problems, such as watery, red, sensitive, or painful eyes; skin problems, such as skin reactions that look like rings, or severe blistering or peeling of the skin; if you develop signs of inflammation of your blood vessels in your skin, including purple spots or redness of your skin on your lower arms, lower legs, or buttocks or large hives on the main part of your body that do not go away within 24 hours and look bruised; or if you develop signs of blood and bone marrow problems, including new fever or fever that does not go away (≥100.4 °F); easy bruising or bleeding that will not stop; unusually pale skin, infection, tiredness, or weakness. Tell your healthcare provider about all your medical conditions and any medicines you take, and if you are pregnant or plan to become pregnant or are breastfeeding.

The most common side effects of TAGRISSO when given alone are low white blood cell counts, low platelet counts, low red blood cell counts (anemia), diarrhea, rash, muscle, bone, or joint pain, changes in your nails, dry skin, mouth sores, and tiredness. These are not all the possible side effects.

Please see the complete Prescribing Information, including Patient Information for TAGRISSO at
https://www.azpicentral.com/pi.html?p...

You may report side effects related to AstraZeneca products here: https://us-aereporting.astrazeneca.com/

This content is intended for US consumers only.

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2024 AstraZeneca. All rights reserved. US-94819 Last Updated 10/24

TAGRISSO® (osimertinib): A Musician's Story

Поделиться в:

Доступные форматы для скачивания:

Скачать видео mp4

  • Информация по загрузке:

Скачать аудио mp3

Похожие видео

Lung Cancer: EGFR Mutation Progression, 2years after Osimertinib/Tagrisso. Active metastasis

Lung Cancer: EGFR Mutation Progression, 2years after Osimertinib/Tagrisso. Active metastasis

Понимание лечения НМРЛ при наличии мутации EGFR

Понимание лечения НМРЛ при наличии мутации EGFR

Angela’s Story

Angela’s Story

Is TAGRISSO® (osimertinib) Right for You?

Is TAGRISSO® (osimertinib) Right for You?

Lung Cancer Stage 4 Update: 8months after taking TAGRISSO - Tumor pills

Lung Cancer Stage 4 Update: 8months after taking TAGRISSO - Tumor pills

Cancer Survivor Story: My Successful Targeted Therapy Treatment | Ashley's Story (2 of 3)

Cancer Survivor Story: My Successful Targeted Therapy Treatment | Ashley's Story (2 of 3)

TAGRISSO Mechanism of Action

TAGRISSO Mechanism of Action

Tagrisso Costa Rica

Tagrisso Costa Rica

20 Medicine of the week: Osimertinib

20 Medicine of the week: Osimertinib

Tumore del polmone non a piccole cellule, con osimertinib adiuvante 90% dei pazienti vivo a 2 anni

Tumore del polmone non a piccole cellule, con osimertinib adiuvante 90% dei pazienti vivo a 2 anni

Osimertinib – TAGRISSO®

Osimertinib – TAGRISSO®

Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung Cancer

Arun Krishna, AstraZeneca: TAGRISSO® Proven Effective at Treating Non-Small Cell Lung Cancer

What to Expect After Diagnosis - TAGRISSO® (osimertinib)

What to Expect After Diagnosis - TAGRISSO® (osimertinib)

EGFR-Mutant Lung Cancer: A Patient's Journey

EGFR-Mutant Lung Cancer: A Patient's Journey

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutions

Osimertinib resistance in non-small cell lung cancer: Pathways and potential solutions

Stephen's Story – Lung Cancer Survivor

Stephen's Story – Lung Cancer Survivor

Elise’s Story

Elise’s Story

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer

Continued use of osimertinib reduces CNS metastasis in EGFR mutant lung cancer

Contre certains cancers du poumon, un traitement prometteur : l’osimertinib | Interview

Contre certains cancers du poumon, un traitement prometteur : l’osimertinib | Interview

Lung Cancer Stage 4 :TAGRISSO (Tumor pill) Side Effects - visible after 9days

Lung Cancer Stage 4 :TAGRISSO (Tumor pill) Side Effects - visible after 9days

© 2025 dtub. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]